Actin‑like protein 8 executes a promoting function in the malignant progression of endometrial cancer: identification of a promising biomarker

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Sm T, Hj M. Endometrial cancer: not your grandmother’s cancer.%A McAlpine JN. Cancer. 2016;122(18):2787–2798.
   PubMed Web of Science ®Google Scholar
• Hill EK, Dizon DS. Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs. 2012;72(5):705.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol. 2011;29(24):3278–3285.
   PubMed Web of Science ®Google Scholar
• Lotocki RJ, Copeland LJ, Depetrillo AD, et al. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol. 1983;146(2):141–145.
   PubMed Web of Science ®Google Scholar
• Todd B, Yin X, Ardeshir H, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008;110(2):206–215.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang J, Ni T, et al. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget. 2016;7(18):25328–25339.
   PubMedGoogle Scholar
• Gao Y, Liu T, Huang Y. MicroRNA‐134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Lett. 2016;589(2):207–214.
   Web of Science ®Google Scholar
• Chen S, Sun KX, Liu BL, et al. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer. 2016;15(1):11.
   PubMedGoogle Scholar
• Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014–2021.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32.
   PubMed Web of Science ®Google Scholar
• Chitale DA, Jungbluth AA, Marshall DS, et al. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol. 2005;18(1):119.
   PubMed Web of Science ®Google Scholar
• Li B, Zhu J, Meng L. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma. Mol Med Rep. 2019;19:877–884.
   PubMed Web of Science ®Google Scholar
• Yao J, Caballero OL, Yung WK, et al. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res. 2014;2(4):371–379.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Terai Y, Kawaguchi H, et al. Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer. Cancer Biol Ther. 2013;14(1):13–19.
   PubMed Web of Science ®Google Scholar
• Li Y, Che Q, Bian Y, et al. Autocrine motility factor promotes epithelial-mesenchymal transition in endometrial cancer via MAPK signaling pathway. Int J Oncol. 2015;47(3):1017–1024.
   PubMed Web of Science ®Google Scholar
• Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59(8):1317–1326.
   PubMed Web of Science ®Google Scholar
• Horie K, Yamamoto H, Karube K, et al. Cyclin A is a reliable proliferation marker in endometrial cancer cell lines. Oncol Lett. 2019;17(5):4455–4462.
   PubMed Web of Science ®Google Scholar
• Cui L, Qu C, Liu H. Association study of cell cycle proteins and human papillomavirus in laryngeal cancer in Chinese population. Clin Otolaryngol. 2019;44(3):323–329.
   PubMed Web of Science ®Google Scholar
• Liao Y, He X, Qiu H, et al. Suppression of the epithelial-mesenchymal transition by SHARP1 is linked to the NOTCH1 signaling pathway in metastasis of endometrial cancer. BMC Cancer. 2014;14(1):487.
   PubMedGoogle Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2010;188(1):22–32.
   Google Scholar
• Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2010;100(11):2014–2021.
   Web of Science ®Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.
   PubMedGoogle Scholar
• Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–640.
   PubMed Web of Science ®Google Scholar
• Wang D, Shi W, Tang Y, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression. Oncogene. 2016;36(7):885–898.
   PubMed Web of Science ®Google Scholar
• Kyushima N, Watanabe J, Hata H, et al. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128(6):307–312.
   PubMed Web of Science ®Google Scholar
• Sakuragi N, Nishiya M, Ikeda K, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol. 1994;53(2):183–189.
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 2002;20(10):2417–2428.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005;132(14):3151–3161.
   PubMed Web of Science ®Google Scholar
• Blechschmidt K, Kremmer E, Hollweck R, et al. The E-cadherin repressor Snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol. 2007;16(4):222–228.
   PubMedGoogle Scholar
• Davidson B, Reich R, Risberg B, et al. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol. 2002;64(3):47.
   PubMedGoogle Scholar
• Simi L, Andreani M, Davini F, et al. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer. 2004;45(2):171–179.
   PubMed Web of Science ®Google Scholar
• Zhen Y, Liu J, Huang Y, et al. miR-133b inhibits cell growth, migration, and invasion by targeting MMP9 in non-small cell lung cancer. Oncol Res. 2016;25(7):1109.
   PubMed Web of Science ®Google Scholar
• Hazan R, Phillips G, Rf NL, et al. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148(4):779–790.
   PubMed Web of Science ®Google Scholar
• Han Q, Sun ML, Liu WS, et al. Upregulated expression of ACTL8 contributes to invasion and metastasis and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1749–1763.
   PubMed Web of Science ®Google Scholar
• Sho T, Tsukiyama T, Sato T, et al. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim Biophys Acta. 2011;1813(6):1245–1253.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhang T, Cheng M, et al. TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38(1):104.
   PubMedGoogle Scholar